Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tubulin beta-2A chain (TUBB2A) is a fundamental component of the microtubule cytoskeleton, belonging to the beta-tubulin family of proteins [1.5.2, 1.5.4]. It forms heterodimers with alpha-tubulin to build microtubules, which are essential for maintaining cell structural integrity, facilitating intracellular transport, and enabling the formation of the mitotic spindle during cell division [1.5.3, 1.5.4]. As a class IIa isotype, TUBB2A is predominantly expressed in the brain and is critical for neurogenesis, neuronal migration, and cortical development [1.2.2, 1.3.1].\n\nPathogenic variants in the TUBB2A gene are associated with a spectrum of rare neurodevelopmental disorders known as tubulinopathies, which present with brain malformations, microcephaly, and infantile-onset epilepsy [1.2.2, 1.4.2]. In oncology, TUBB2A is frequently overexpressed in various cancers, such as triple-negative breast cancer and gastric cancer, where it correlates with poor prognosis and resistance to chemotherapy [1.2.1, 1.5.2]. Therapeutic agents targeting tubulin, including taxanes (e.g., paclitaxel) and vinca alkaloids (e.g., vincristine), interact with TUBB2A to disrupt microtubule dynamics, leading to cell cycle arrest and apoptosis [1.2.1, 1.3.1].
Microtubule stabilization and destabilization through binding to the taxane, vinca alkaloid, or colchicine sites on the tubulin heterodimer.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin beta-2A chain (TUBB2A) (TUBB2A).